CureVac’s Final Chapter: Shareholders Seal Merger Fate

A significant deadline has arrived for one of Germany’s most closely watched biotech narratives. The offer period for BioNTech’s exchange tender concludes today, marking the irreversible end of CureVac’s journey as an independent publicly traded entity. For investors still holding shares, this final cutoff carries specific implications, while the path toward an inevitable delisting from public markets is now clear.

The Inevitable Delisting Process

The direct consequence for CureVac’s equity is its imminent disappearance from the Nasdaq exchange. Following the approved legal merger, CureVac will effectively be absorbed into a new entity or integrated wholly, allowing BioNTech to consolidate the mRNA technology platform without the operational overhead of a separate listed company. Trading activity in recent sessions has exhibited a classic arbitrage pattern, with the share price decoupling from company-specific news and instead tracking the valuation implied by the BioNTech offer. Liquidity is expected to evaporate rapidly as the delisting process advances, closing a notable chapter in Germany’s biotechnology sector.

Overwhelming Shareholder Mandate

The transition was decisively paved by CureVac’s shareholders. During a recent extraordinary general meeting, investors granted their approval with an overwhelming majority of 99.16 percent, providing a clear mandate for the transaction. This near-unanimous vote underscores a broad market consensus that the company’s future lies within the BioNTech corporate structure. With this authority, management can proceed immediately with the legal merger and integration following the technical conclusion of the offer period, leaving no practical doubt about the takeover’s completion.

Should investors sell immediately? Or is it worth buying CureVac?

Fixed Terms and a Critical Deadline

The exit terms for investors are firmly established. The final exchange ratio is set at 0.05363 BioNTech American Depositary Shares (ADS) for each single CureVac share held. The pivotal cutoff occurred today, Wednesday, with the acceptance period officially expiring at 9:00 a.m. Eastern Time (ET).

Shareholders who did not tender their holdings through their custodian bank by this deadline now face the “Post-Offer Reorganization” process. This mechanism is designed to squeeze out remaining minority stakeholders—albeit under the same economic terms—but often involves bureaucratic complexities and a different timeline. The execution of this squeeze-out is contingent upon BioNTech having reached the minimum acceptance threshold of 80 percent of CureVac’s outstanding shares. For investors, the remaining step is simply to await the official confirmation of the merger’s completion.